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Glucocorticoids induce apoptosis in lymphocytes by causing the release of cytochrome c into the cytosol; however, the events in
the signaling phase between translocation of the steroid–receptor complex to the nucleus and the release of cytochrome c have not
been elucidated. Previously, we found that, in response to steroid treatment, WEHI7.2 mouse thymic lymphoma cells overexpressing
catalase (CAT38) show delayed apoptosis (delayed cytochrome c release) compared to the parental cells, while Bcl-2 overexpressing
cells (Hb12) are protected from steroid-induced apoptosis. In lymphocytes, glucocorticoid treatment decreases glucose uptake. Both
glucose deprivation and the attendant ATP drop are known inducers of apoptosis. Therefore, we used 31P and 1H NMR spectroscopy
to compare metabolic profiles of WEHI7.2, CAT38 and Hb12 cells in the presence and absence of dexamethasone to determine: (1)
whether glucocorticoid effects on glucose metabolism contribute to the mechanism of steroid-induced apoptosis; and (2) whether
catalase or Bcl-2 overexpression altered metabolism thereby providing a mechanism of steroid resistance. Loss of mitochondrial
hexokinase activity was correlated to the induction of apoptosis in WEHI7.2 and CAT38 cells. CAT38 and Hb12 cells have an
altered basal metabolism which includes increases in hexokinase activity, lactate production when subcultured into new medium, use
of mitochondria for ATP production and potentially increased glutaminolysis. These data suggest that: (1) glucocorticoid effects on
glucose metabolism may contribute to the mechanism of steroid-induced lymphocyte apoptosis; and (2) the altered metabolism seen
in catalase and Bcl-2 overexpressing cells may contribute to both the steroid resistance and increased tumorigenicity of these
variants.
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1. Introduction glucocorticoids to induce apoptosis in lymphoid tissuesGlucocorticoid-induced lymphocyte apoptosis is a well-
documented process that is critical physiologically for the
sorting of immature lymphoid cells [1]. The ability of0167-4889/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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leukemias and lymphomas; however, the development of
resistance can limit the efficacy of treatment [2–4].
Apoptosis due to glucocorticoid treatment depends on
binding of the steroid to a cytosolic receptor and the
translocation of the steroid–receptor complex to the nu-
cleus where the complex exerts an effect on transcription
[5]. An unknown series of events then transpires (the
signaling phase) resulting in the release of cytochrome c
from the mitochondria (the committed step), formation of
the apoptosome and activation of caspases (the execution
phase) [6,7]. Some of the resistance to steroids observed in
patients and in cell culture can be attributed to a lack of or
decrease in the number of functional glucocorticoid recep-
tors [2,4,8–10]. However, in some individuals and tissue
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ations [11–13].
Using WEHI7.2 mouse thymic lymphoma tissue culture
cells treated with dexamethasone, a synthetic glucocorti-
coid, as a model system, we found that overexpression of
the antioxidant enzyme catalase or the antioxidant protein
thioredoxin confers resistance to steroid-induced apoptosis
[14,15]. Similarly, a population of cells selected for resis-
tance to hydrogen peroxide, which show increases in a panel
of antioxidant enzymes, are also resistant to steroid-induced
apoptosis [16]. The steroid-resistant variants all show a
delay or lack of cytochrome c release from the mitochondria
after dexamethasone treatment when compared to the pa-
rental cells [14,16]. This suggests that an increased antiox-
idant defense alters the signaling phase of steroid-induced
apoptosis.
In this study, we have addressed the question of whether
glucocorticoid-mediated effects on glucose and energy me-
tabolism contribute to the induction of apoptosis in lym-
phocytes. Glucocorticoids stimulate gluconeogenesis in the
liver and decrease glucose metabolism in a number of
tissues including lymphoid tissues to spare glucose for the
brain [17–20]. Glucose deprivation and the attendant drop
in ATP have each been implicated in the induction of
apoptosis in multiple systems [21] including lymphoid cells,
e.g. Refs. [22,23].
One possible model to explain the steroid resistance of
cells overexpressing antioxidant defense enzymes is that
these cells are protected under conditions of glucose depri-
vation. Glucose deprivation can result in an increase in
reactive oxygen species (ROS) production as cells rely on
amino acid and fatty acid metabolism in the mitochondria to
maintain ATP [24,25]. Increased antioxidant defenses may
protect against the oxidant stress that can occur with this
switch. Alternatively, overexpression of antioxidant defense
enzymes may alter the basal metabolism of the cell either by
altering the redox environment or the demand for reducing
equivalents, e.g. NADPH. Alterations in basal metabolism
may also affect the dexamethasone response.
Using 31P and 1H NMR spectroscopy, we have gener-
ated metabolic profiles in the presence and absence of
dexamethasone for the steroid-sensitive WEHI7.2 cells;
CAT38 cells, which express 1.4-fold parental cell catalase
and show delayed apoptosis; and Hb12 cells which over-
express Bcl-2 and are protected from dexamethasone-
induced apoptosis. We examined a time course of meta-
bolic changes in the WEHI7.2 cells to determine whether
changes in glucose metabolism occur prior to the release
of cytochrome c and thus could indicate a signaling event.
We compared basal metabolism in WEHI7.2, CAT38 and
Hb12 cells to see whether overexpression of catalase or
Bcl-2 altered metabolism. Finally, we compared the met-
abolic alterations due to dexamethasone treatment of the
steroid-resistant variants to those in the parental cells to
suggest whether steroid resistance is connected to altered
metabolism.2. Materials and methods
2.1. Chemicals and cellular protein determination
All chemicals and drugs were purchased from Sigma
Chemical Co. (St. Louis, MO) unless otherwise noted.
Cellular protein content was determined using the BCA
protein assay kit and the manufacturer’s protocol (Pierce
Chemical Co., Rockford, IL) except where specified.
2.2. Cell culture and drug treatment
WEHI7.2 mouse thymic lymphoma tissue culture cells
[26] were obtained from Dr. Roger Miesfeld (University of
Arizona, Tucson, AZ). Cells were cultured, in suspension, in
Dulbecco’s Modified Eagle Medium-low glucose (GIBCO-
BRL Products, Grand Island, NY) supplemented with 10%
calf serum (Hyclone Laboratories, Logan, UT) at 37 jC in a
5% CO2 humidified environment. These cells were main-
tained in exponential growth at a density between 0.02 and
2 106 cells/ml. WEHI7.2 cells stably transfected with and
overexpressing human bcl-2 (Hb12), also obtained from Dr.
Miesfeld, were constructed and maintained as described by
Lam et al. [27]. Catalase-overexpressing WEHI7.2 cells
(CAT38) were constructed and cultured in the presence of
800 Ag/ml G418 (GIBCO-BRL) to ensure continued cata-
lase expression as described by Tome et al. [14]. One week
prior to each sampling, the cells were subcultured in the
absence of selection drug. Immediately before each exper-
iment, live cells were separated from those that underwent
spontaneous apoptosis using Ficoll-Plaque Plus reagents
and the manufacturer’s suggested protocol (Amersham
Pharmacia Biotech, Piscataway, NJ). Cells were subcultured
into medium and incubated in the presence of 1 AM
dexamethasone or ethanol as a vehicle control (final
conc. = 0.01%) for indicated times before harvest.
2.3. Annexin binding
Cells were harvested by centrifugation (500 g for 5
min) and washed twice with PBS. Cells were incubated with
FITC-labeled annexin V, which binds to phosphatidylserine
(PtdSer), and propidium iodide, which fluoresces when
bound to DNA, in PBS according to the manufacturer’s
instructions (Apoptosis Detection Kit, R&D Systems, Min-
neapolis, MN). Cellular fluorescence in two channels was
analyzed using a FACScan flow cytometer with CellQuest
software (Becton Dickinson, San Jose, CA). Ten thousand
cells were analyzed per sample. This allowed the separation
of the cells into three groups: (1) cells that showed no
fluorescence in either channel were considered live; (2) cells
that showed increased fluorescence only in the FITC chan-
nel were considered apoptotic; and (3) cells that showed
increased fluorescence in both channels were considered
late apoptotic/necrotic because the membrane was compro-
mised. Only cells that were annexin V-positive and propi-
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study.
2.4. Glucose uptake
Glucose uptake was measured by a procedure modified
from Ref. [28]. Briefly, cells were incubated for 16 h in the
presence or absence of dexamethasone. Cells were pelleted
by centrifugation (500 g for 5 min) and resuspended in
PBS containing 200 AM 6-(N-(7-nitrobenz-2-oxa-1,3-
diazol-4-yl)amino)-6-deoxyglucose (6-NBDG) (Molecular
Probes, Eugene, OR) and 5 Ag/ml propidium iodide. Sam-
ples were incubated 30 min at 37 jC then an aliquot from
the cell culture was pipetted into stopping solution (DMEM
with 10% calf serum containing 200 AM phloretin). Cells
were pelleted by centrifugation (500 g for 5 min) and
resuspended in 1-ml new stopping solution. Samples were
analyzed using a FACScan flow cytometer with CellQuest
software (Becton Dickinson): excitation 488 nm/emission
540 nm. Ten thousand cells were analyzed per sample.
Propidium iodide positive cells were excluded from the
analysis. The mean fluorescence of cells treated with 200
AM phloretin for 30 min before addition of 6-NBDG was
subtracted from each sample before analysis of the dexa-
methasone effects to correct for nonspecific binding of 6-
NBDG to the cell surface.
2.5. Enzyme activities
Cells were harvested by centrifugation (500 g for 5
min at 4 jC), washed twice with PBS and sonicated into the
enzyme-specific lysis buffer. The sonicate was clarified by
centrifugation (10,000 g for 10 min) and the supernatant
used for enzyme and protein assays. Phosphate-dependent
glutaminase was measured as described by Curthoys and
Lowry [29] by monitoring the formation of NADH using a
spectrophotometer. NADH formation in each sample after
heating for 10 min at 50 jC was also measured to quantify
the glutamic acid present in the original sample. The NADH
formation in the absence of heat minus the NADH forma-
tion in the presence of heat was used to calculate glutamin-
ase activity. Phosphate-independent glutaminase activity
was not seen. Lactate dehydrogenase activity was measured
by monitoring the rate of NADH loss after the addition of
pyruvate using the method of Sekine et al. [30]. Glutamin-
ase and lactate dehydrogenase activities were calculated
using an extinction coefficient of 6.3 mM 1 cm 1. Enzyme
activities were normalized to cellular protein content.
For hexokinase activity measurements, the sample was
separated into mitochondrial and cytosolic fractions using
the protocol of Bossy-Wetzel and Green [31]. The mito-
chondrial pellet was sonicated into buffer containing: 45
mM Tris–HCl, pH 8.2; 50 mM KH2PO4; 10 mM glucose;
10 mM monothioglycerol; 0.5 mM ethylenediamine tetra-
acetic acid; and 0.2% Triton X-100, and then the sample
was clarified by centrifugation (10,000 g for 10 min at4 jC). Hexokinase activity was measured as described by
Gottlob et al. [32] and activity calculated based on a
standard curve. Sample protein was measured using the
Bradford reagent [33], with bovine serum albumin as a
standard. Hexokinase activity was normalized to cytosolic
or mitochondrial protein content. Total hexokinase activity
was calculated from the activities measured in both
fractions.
2.6. Biochemical ATP measurements
ATP was measured using the Bioluminescent Somatic
Cell Assay Kit (Sigma) according to the manufacturer’s
instructions. This assay depends on the light emitted when
the sample ATP is added to luciferin in the presence of
firefly luciferase. Luminescence was quantitated using a
TD-20/20 Luminometer (Turner Designs, Sunnyvale, CA).
Protein was measured in parallel samples and ATP normal-
ized to cellular protein content. To measure ATP without
mitochondrial ATP production, cells were treated with 10
AM carbonyl cyanide m-chlorophenylhydrazine (CCCP) for
2 h before cell harvest [34].
2.7. NMR spectroscopy
Approximately, 6–8 108 cells from cultures at a den-
sity of 7–8 105 cells/ml were harvested by centrifugation
(500 g for 5 min at 4 jC) for each timepoint/treatment.
Samples were prepared, NMR spectra acquired and ana-
lyzed and then metabolites normalized to cellular protein
content as previously described [35,36]. Briefly, after har-
vest, cells were washed and then fixed by adding methanol.
Chloroform and water were added to the sample, then the
phases separated by incubation at 20 jC overnight and
subsequent centrifugation (12,000 g for 40 min at 4 jC).
Solvents were evaporated from the aqueous phase and the
sample lyophilized. Samples were stored at  80 jC until
analysis. Before spectroscopy, the lyophilizate was dis-
solved in a D2O solution containing 50 mM 1,2-diamine-
tetraacetic acid. 31P and 1H NMR spectra were obtained at
202.5 and 500.1 MHz, respectively, on a vertical, narrow-
bore 11.7 Bruker Avance DRX 500 FT NMR spectrometer
(Bruker, Rheinstetten, Germany) using a broadband probe
for 5-mm tubes. For 31P spectra the acquisition parameters
were: acquisition time (AQ) = 2.025 or 4.05 s, correspond-
ing to 32 or 64 k data points, respectively; pulse width
(PW) = 7.8 As; pulse repetition time (TR) = 13 s; and spec-
tral width (SW) = 8 kHz (1500 transients). Methylene
diphosphonate was used as an external reference for 31P
spectra as previously described [35]. For water-suppressed
1H spectra, the acquisition parameters were: AQ= 3.28 s;
PW=2.0 As; TR = 5.3 s; SW= 5 kHz (128 transients). The
phosphocholine peak was used as a secondary reference in
the 1H spectra. Signals were identified by the addition of
small quantities of commercially available original com-
pounds to representative extracts and metabolites quantitat-
Fig. 2. Comparison of glucose uptake in WEHI7.2, CAT38 and Hb12 cells
in the absence and presence of dexamethasone. Values were corrected for
nonspecific binding of the probe and normalized to uptake in the absence of
dexamethasone (% control) for each cell variant. Each bar represents the
mean uptake for vehicle (ethanol)-treated (open bars) or dexamethasone-
treated (solid bars) cells + S.E. (n= 3). Asterisks denote significantly
different from the ethanol-treated samples for the same cell variant
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follows: NDP=(NTPg +NDPh)NTPh.
2.8. Statistics
Data are reported as meanF S.E. of three or four inde-
pendently collected samples for the NMR data and the hexo-
kinase activity assays. For all other measurements, a repre-
sentative experiment, from at least two replicates, is shown.
Each experiment consisted of three independent samples for
each combination of cell variant, treatment and timepoint and
is reported as the meanF S.E. of these samples.
Fisher’s protected least significant difference test for
multiple comparisons was used to test for significant differ-
ences between timepoints (StatView, SAS Institute, Cary,
NC). Some of the sample means were compared by t-tests
assuming unequal variances using the algorithm in Excel
(Microsoft Corp., Redmond WA) or the formula from
Moore and McCabe [37]. Samples were considered signif-
icantly different if PV 0.05.
( PV 0.05). This is a representative experiment which has been replicated.3. Results
3.1. Apoptosis
As a measure of apoptosis in WEHI7.2, CAT38 and
Hb12 cultures, we compared the time course of PtdSerFig. 1. Comparison of apoptosis in WEHI7.2 (.), CAT38 (n) and Hb12 (x)
cell cultures after the addition of dexamethasone (time = 0). C values are the
percentage of apoptotic cells 24 h after subculture in the absence of
dexamethasone. Each symbol represents the mean percentage of the cells
that are annexin-positive and propidium iodide-negative. Values are
meanF S.E. (n= 3). Where error bars are not visible they are contained
within the symbol. Asterisks denote significantly different from C values for
the same cell variant ( PV 0.05). This is a representative experiment which
has been replicated. This figure has been reprinted from Tome et al. [36].externalization [38] in response to dexamethasone treatment
(Fig. 1). WEHI7.2 cells showed a significant increase in
PtdSer externalization by 16 h after the addition of dexa-
methasone. In CAT38 cells the increase was delayed,
appearing at 28 h after treatment. No significant increase
in PtdSer externalization was seen in Hb12 cells over this
time course. Previously we have shown that the release of
cytochrome c into the cytosol is detectable beginning at 16
h post treatment in the WEHI7.2 cells and at 32 h in the
CAT38 cells [14]. These data suggest that PtdSer external-
ization occurs slightly prior to or concomitant with the
commitment to undergo apoptosis. Spontaneous rates of
apoptosis in these cultures were also significantly different
as shown by the PtdSer externalization in exponentially
growing untreated cells (Fig. 1). WEHI7.2 cell cultures
showed the most apoptosis, CAT38 cultures an intermediate
amount and Hb12 cells the least.
3.2. Glucose uptake
Glucocorticoids decrease glucose uptake in lymphoid
cells [17,20,39]. To determine whether dexamethasone
decreased glucose uptake similarly in the steroid-sensitive
and steroid-resistant cells, we compared glucose uptake after
dexamethasone treatment in WEHI7.2, CAT38 and Hb12
cells (Fig. 2). Glucose uptake was significantly decreased in
the steroid-sensitive and steroid-resistant cells after 16 h in
dexamethasone. The greatest decrease was seen in the
WEHI7.2 cells; however, a substantial decrease also oc-
curred in the CAT38 and Hb12 cells. In the presence of
dexamethasone in WEHI7.2 cells, glucose uptake (as a
percentage of control) was significantly less than in Hb12
cells, but not significantly different from CAT38 cells.
M.E. Tome et al. / Biochimica et BiopTo determine whether the glucose and energy metabo-
lism differed in the steroid-sensitive and -resistant cells after
the dexamethasone-induced decrease in glucose uptake, we
used 31P and 1H NMR. This allowed us to compare the
metabolites shown in Fig. 3 and examine metabolism more
globally.Fig. 3. Representative NMR spectra from WEHI7.2 cultured for 24 h in ethanol. (A
two insets show portions of the spectrum in greater detail. (B) 1H spectrum indica
included as a reference. Abbreviations include: Gro-3-P (glycerol 3-phosphate); UD
(alanine); lac (lactate).3.3. Glycolysis
Glycolysis involves a number of six- and three-carbon
phosphate intermediates. Alterations in this group of inter-
mediates can indicate an alteration in glucose metabolism
[40]; blocking a specific enzyme can result in an increase in
hysica Acta 1693 (2004) 57–72 61) 31P spectrum indicating the metabolites quantified from these spectra. The
ting the metabolites quantified from these spectra. Phosphocholine (PC) is
P-Hex (UDP-hexoses); asp (aspartate); gln (glutamine); glu (glutamate); ala
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dexamethasone-treated lymphoblastic T cell line suggest
that dexamethasone down-regulates multiple enzymes in
glycolysis as opposed to targeting only one step [42]. As
an overall indicator of glucose metabolism, we compared
the sum of the NMR signals in the region where these
glycolytic intermediates are seen [35,43], labeled hexose/
triose phosphate, in cells overexpressing catalase or Bcl-2 to
that in WEHI7.2 cells (Fig. 4). In general, both CAT38 and
Hb12 cells had a higher concentration of these metabolites
than WEHI7.2 cells. In the presence of dexamethasone these
metabolites, as a group, slightly increased in WEHI7.2 cells,
slightly decreased in CAT38 cells and showed no consistent
change in Hb12 cells. When the peaks in this region were
examined individually, no consistent change was seen for
any one metabolite (data not shown). Therefore, these data
are more consistent with a general down-regulation ofFig. 4. Comparison of hexose/triose phosphate, lactate, NAD and UDP-hexose con
presence of dexamethasone. Each bar represents the mean metabolite concentra
cells + S.E. (n= 3 or 4). Asterisks denote significantly different from the ethanol-tglycolysis by dexamethasone, rather than a block at any
one enzymatic step.
Lactate production and lactate dehydrogenase (LDH) are
also reportedly decreased by glucocorticoids in lymphoid
cells [18,42]. In the absence of dexamethasone, lactate and
LDH were highest in WEHI7.2, CAT38 and Hb12 cells 12 h
after subculture into new medium (Figs. 4 and 5). Both
lactate and LDH were higher in CAT38 cells than in
WEHI7.2 cells and were the highest in Hb12 cells at this
timepoint. Lactate and LDH decreased over time, but faster
and to a greater extent in the CAT38 and Hb12 cells than in
the WEHI7.2 cells. In dexamethasone, lactate also de-
creased over time in the WEHI7.2 cells such that the
concentration after 32 h in drug was significantly less than
the concentration in the absence of drug. In both CAT38 and
Hb12 cells, the pattern of lactate loss and LDH decrease was
fairly similar in the presence of dexamethasone to that incentration over time in WEHI7.2, CAT38 and Hb12 cells in the absence and
tion in ethanol-treated (open bars) or dexamethasone-treated (solid bars)
reated sample at the same timepoint from the same cell variant ( PV 0.05).
Fig. 5. Comparison of lactate dehydrogenase activity in WEHI7.2, CAT38 and Hb12 cells in the absence and presence of dexamethasone. Each bar represents
the mean activity in ethanol-treated (open bars) or dexamethasone (solid bars) cells + S.E. (n= 3). Asterisks denote significantly different from the ethanol-
treated sample at the same timepoint from the same cell variant ( PV 0.05). This is a representative experiment which has been replicated.
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Hb12 cells are more lactogenic than WEHI7.2 cells when
subcultured into new medium and that dexamethasone does
not down-regulate LDH.
NAD (Fig. 4) remained fairly constant in WEHI7.2,
CAT38 and Hb12 cells in the absence of dexamethasone,
although the NAD concentration in Hb12 cells was slightly
increased compared to WEHI7.2 cells. In the presence of
dexamethasone, the NAD decreased over time in WEHI7.2
and CAT38 cells which undergo apoptosis, but not in the
steroid-resistant Hb12 cells. A decrease in NAD is consis-
tent with the activation of poly(ADP-ribose)polymerase
(PARP), which uses NAD as a substrate [44]. Dexametha-
sone is known to activate PARP in B chronic lymphocytic
leukemia cells [45]. NADH was not seen in these spectra.
UDP-hexose concentration varied more in both CAT38
and Hb12 cells than in WEHI7.2 cells independent of
dexamethasone treatment (Fig. 4). This suggests that syn-
thesis and further metabolism of activated sugars is in-
creased in the resistant cells. Activated sugars participate
in numerous pathways including glycogen synthesis and
detoxification of xenobiotics [17]. More active metabolism
of these compounds may reflect alterations in any of these
pathways.
3.4. ATP
A decrease in ATP can trigger apoptosis in some systems
[21,23] with the final ATP concentration affecting whether a
cell undergoes apoptosis or necrosis [46]. ATP decreases
have been reported in lymphoid cells undergoing apoptosis
in response to glucose deprivation or dexamethasone treat-ment [18,23,47,48]; anti-apoptotic Bcl-2 family members
can either protect cells from the ATP decrease or protect
downstream from the ATP loss [18,23,47].
As shown in Fig. 6, WEHI7.2 cells incubated in the
presence of dexamethasone initially showed a slight in-
crease in ATP (12 h) and then a continuing decline in ATP
concentration. CAT38 cells had a similar pattern of ATP
decline; however, although Hb12 cells showed a decline in
ATP concentration, it was neither as sharp nor to as great an
extent as that in WEHI7.2 or CAT38 cells. The initial
increase in ATP in WEHI7.2 cells after dexamethasone
treatment suggests that ATP depletion does not occur early
enough to be a triggering event.
One possibility is that ATP is dephosphorylated causing a
buildup of ADP and Pi. The ATP/ADP ratio can be critical
for apoptosis [44,49]. ATP, NTP (which is primarily ATP)
and NDP all showed similar patterns of decreasing concen-
tration in the presence of dexamethasone (Fig. 6) suggesting
that the loss of ATP is not just a dephosphorylation event.
The drop in Pi in WEHI7.2 and CAT38 cells that are
undergoing apoptosis is consistent with this interpretation.
3.5. Amino acids
One of the possible fates of glucose is conversion to
pyruvate and then into alanine, building up an alanine pool
that can be metabolized via the tricarboxylic acid (TCA)
cycle in the mitochondria to produce ATP. WEHI7.2,
CAT38 and Hb12 cells all had a substantial alanine pool
that was fairly constant in the absence of dexamethasone
(Fig. 7). CAT38 cells generally had the highest concentra-
tion. In the presence of dexamethasone, this pool decreased
Fig. 6. Comparison of ATP, Pi, NTP and NDP concentration over time in WEHI7.2, CAT38 and Hb12 cells in the absence and presence of dexamethasone.
Each bar represents the mean metabolite concentration in ethanol-treated (open bars) or dexamethasone-treated (solid bars) cells + S.E. (n= 3 or 4). Asterisks
denote significantly different from the ethanol-treated sample at the same timepoint from the same cell variant ( PV 0.05).
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provide a source of energy during loss of glucose.
Lymphocytes are very adept at using glutamine as an
energy source via glutaminolysis [50]. Mitochondrial gluta-
minase can convert glutamine to glutamate, which can then
be converted to a-ketoglutarate by glutamate dehydrogenase
or aspartate transaminase [50]. a-Ketoglutarate can then
cycle through a portion of the TCA cycle to form ATP. Even
in the presence of glucose, lymphocytes metabolize gluta-
mine for the production of energy [50–52]; however, in the
absence of glucose, this pathway may increase in impor-
tance. Glucocorticoids stimulate glutaminase activity in rat
mesenteric lymph node lymphocytes [53]. This suggests the
possibility that glucocorticoid treatment may cause a switch
from glycolysis to glutaminolysis for ATP production.
When lymphocytes or lymphoid-derived tumor cell lines
are cultured in the presence of radiolabeled glutamine, the
label is recovered primarily in glutamate, ammonia, aspar-tate and CO2 [50,51,54,55]. Therefore, we examined gluta-
mine, glutamate and aspartate in these cells to determine
whether alterations occurred that would be consistent with a
switch to glutaminolysis.
In the absence of dexamethasone, the WEHI7.2 cells
showed little change in glutamine, glutamate or aspartate
(Fig. 7). However, both the CAT38 and Hb12 cells showed
a decrease in glutamine and glutamate that was correlated
with an increase in aspartate. In the dexamethasone-treated
WEHI7.2 cells, there was a significant decrease in gluta-
mine and glutamate over time and a tendency toward a
decrease in aspartate. Both CAT38 and Hb12 cells also
showed a decrease in glutamine and glutamate in the
presence of dexamethasone. However, CAT38 cells showed
an increase in aspartate out to 32 h and then a drop at 40 h
when the cells are undergoing apoptosis. Hb12 cells also
showed an increase in aspartate over time in the presence of
dexamethasone with the highest concentration at 40 h. No
Fig. 7. Comparison of amino acid concentration over time in WEHI7.2, CAT38 and Hb12 cells in the absence and presence of dexamethasone. Each bar
represents the mean metabolite concentration in ethanol-treated (open bars) or dexamethasone-treated (solid bars) cells + S.E. (n= 3 or 4). Asterisks denote
significantly different from the ethanol-treated sample at the same timepoint from the same cell variant ( PV 0.05).
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paring the three cell variants and no dexamethasone-induced
increase in glutaminase activity were seen (data not shown).
3.6. ATP production
One possible interpretation of these data is that the ability
to use the mitochondria for ATP production is critical for
survival in the presence of dexamethasone. To compare the
mitochondrial contribution to the ATP pool in WEHI7.2,
CAT38 and Hb12 cells we measured the intracellular ATP in
the absence and presence of CCCP, an uncoupler of mito-
chondrial respiration (Fig. 8). In these experiments, the ATP
in the absence of CCCP represents the ATP pool with
contributions from both glycolysis and oxidative phosphor-
ylation; ATP in the presence of CCCP represents the pool
without contributions from oxidative phosphorylation; and
the difference between the two measurements represents themitochondrial ATP contribution under these experimental
conditions. In the absence of dexamethasone, the CAT38
cells produced slightly more ATP by oxidative phosphory-
lation than the WEHI7.2 cells. Hb12 cells showed a greater
mitochondrial ATP production than CAT38 cells at this
timepoint. After 24 h in the presence of dexamethasone,
the WEHI7.2 cells are undergoing apoptosis, with consid-
erable release of cytochrome c into the cytosol [14]. Only a
small amount of ATP was produced by the mitochondria
under these conditions. Neither CAT38 nor Hb12 cells
showed evidence of apoptosis after 24 h in the presence
of dexamethasone and the mitochondria were still producing
similar amounts of ATP as in the EtOH-treated cells. After
40-h culture in the absence of dexamethasone, CAT38 cells
still produced a considerable amount of ATP from the
mitochondria. In the presence of dexamethasone, after 40 h
CAT38 cells show increased cytochrome c release [14] and
the mitochondrial ATP production was decreased. After 40 h
Fig. 8. Comparison of cellular ATP in WEHI7.2, CAT38 and Hb12 cells after treatment with CCCP in the presence of ethanol (E) or dexamethasone (D). (A)
Intracellular ATP pool after treatment with DMSO vehicle (solid bars) or 10 AM CCCP (open bars) for 2 h before harvest. (B) Amount of ATP produced by
oxidative phosphorylation in the presence of ethanol (E, open bars) or dexamethasone (D, solid bars) under these experimental conditions. Each bar represents
the mean ATP concentration + S.E. (n= 3). This is a representative experiment which has been replicated.
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mitochondria in the EtOH-treated Hb12 cells had signifi-
cantly increased compared to the 24-h sample. In the
presence of dexamethasone, although the mitochondrial
ATP production was less than in the 40 h EtOH-treated
sample, mitochondria were still capable of ATP production
similar to that in EtOH-treated CAT38 cells.
3.7. Hexokinase
Previous studies have shown that increased hexokinase
can protect against apoptosis caused by growth factor
withdrawal or exposure to oxidants [32,56,57]. For apopto-
sis due to growth factor withdrawal in a pro-B-cell line,
FL5.12, loss of hexokinase from the mitochondrial mem-
brane is a key event [32]. The authors propose that the
availability of glucose or a metabolizable substrate forhexokinase maintains the mitochondrial association of this
enzyme [32]. These data suggested the possibility that
dexamethasone effects on hexokinase could contribute to
the mechanism of steroid-induced apoptosis because: (1)
microarray data show that dexamethasone treatment down-
regulates hexokinase in T cells [42]; and (2) dexamethasone
treatment decreased the ability of WEHI7.2, CAT38 and
Hb12 cells to take up glucose. To test this possibility, we
examined total, mitochondrial-associated and cytosolic
hexokinase (Fig. 9).
Total hexokinase activity on a cellular basis is signifi-
cantly higher in both CAT38 and Hb12 than in WEHI7.2
cells in the EtOH-treated controls (Fig. 9A). In WEHI7.2
cells and the steroid-resistant variants, cultured in the
presence of dexamethasone, the hexokinase activity was
lower than that in the EtOH-treated controls. This suggests
that dexamethasone treatment suppresses hexokinase activ-
Fig. 9. Comparison of hexokinase activity in WEHI7.2, CAT38 and Hb12 cells in the absence or presence of dexamethasone. (A) Total hexokinase activity. (B)
Top panel: Mitochondrial fraction hexokinase activity. Bottom panel: Cytosolic fraction hexokinase activity. Each bar represents the mean hexokinase activity
in ethanol-treated (open bars) or dexamethasone-treated (solid bars) cells + S.E. (n= 4).
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time in dexamethasone depending on the steroid sensitivity
of the cells.
In WEHI7.2 cells there is a significant loss of hexokinase
activity between 12 and 24 h in dexamethasone when the
cells are undergoing apoptosis. In CAT38 cells there is a
significant loss between 24 and 40 h in dexamethasone,
when other signs of apoptosis are appearing in these cells. In
contrast, in Hb12 cells, the amount of hexokinase is similar
at 24 and 40 h in drug.The pattern in total hexokinase activity is fairly closely
reflected in the pattern of mitochondrial hexokinase activity
(Fig. 9B). This is particularly true of the dexamethasone-
treated samples where there was a significant decrease
between 12 and 24 h in the WEHI7.2 cells and in the
CAT38 cells where a significant decrease occurred between
24 and 40 h. In Hb12 cells, mitochondrial hexokinase was
similar at 24 and 40 h in the presence of dexamethasone.
Measurement of cytosolic hexokinase did not correlate
with apoptosis sensitivity. Cytosolic hexokinase (Fig. 9B)
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at 24 h in the absence of dexamethasone. CAT38 cells had
significantly higher hexokinase activity than the other two
variants at this timepoint. In WEHI7.2 and Hb12 cells,
dexamethasone caused no significant change in cytosolic
hexokinase activity. In the CAT38 cells cytosolic hexoki-
nase activity decreased by 40 h in dexamethasone.4. Discussion
Use of 31P and 1H NMR, in combination with enzyme
activity assays, has provided us with an integrated overview
of the metabolic effects caused by glucocorticoid treatment
in the steroid-sensitive WEHI7.2 cells and the steroid-
resistant catalase and Bcl-2 overexpressing cells. The met-
abolic differences seen in the sensitive vs. resistant cells
may prove significant in light of the current interest in the
role of mitochondrial metabolism in apoptosis.
4.1. Metabolic phenotype is altered by catalase or Bcl-2
overexpression
Overexpression of catalase or Bcl-2 has resulted in
variants with an altered metabolic phenotype. Both variants
show an increase in hexose/triose phosphate concentration
coupled with an increase in hexokinase activity suggesting a
potential increase in glycolysis. Increased hexokinase can
increase glycolysis by providing additional glucose 6-phos-
phate for further metabolism [40,56,58,59]. Both variants
also appear to rely more on the mitochondria for ATP
production; this is particularly true of the Hb12 cells and
may be a reflection of increased mitochondrial-associated
hexokinase. Increased hexokinase bound to the mitochon-
dria would allow for more efficient use of ATP produced by
the mitochondria and, by proximity, increase the transport of
ADP back into the mitochondria [58]. Increased mitochon-
drial ADP can stimulate the TCA cycle at the isocitrate
dehydrogenase step [58].
Both CAT38 and Hb12 cells are more lactogenic than
WEHI7.2 cells when subcultured into new medium, prob-
ably due to the greater induction of lactate dehydrogenase,
but also show a greater decrease in cellular lactate over time
than the WEHI7.2 cells. Loss of lactate can reflect either
export or further metabolism. Lymphocytes contain both the
inducible LDH-A which favors the conversion of pyruvate
into lactate and the constitutive LDH-B which favors the
formation of pyruvate from lactate [60]. The increase in
mitochondrial ATP production in the CAT38 and Hb12 cells
may also reflect the further metabolism of lactate through
pyruvate and the TCA cycle after a longer time in culture.
In addition to a potential for increased glycolysis, the
metabolic profile of the CAT38 and Hb12 cells fits with
increased glutaminolysis particularly after a longer time in
culture. Glutaminolysis is a mitochondrial process whereby
glutamine is metabolized to produce ATP [50,61]. In lym-phoid cells, this process generates ammonia, aspartate and
CO2 [50,52]. Both CAT38 and Hb12 cells show a decrease
in glutamine and glutamate over time in culture that is
coupled with an increase in aspartate. Glutamine is used for
numerous reactions in cells including glutathione synthesis
and de novo synthesis of purines and pyrimidines. Gluta-
thione synthesis would account for the decrease in gluta-
mine and glutamate, but not the increase in aspartate [62].
De novo purine and pyrimidine synthesis would be expected
to use glutamine and aspartate, but produce glutamate [17].
The pattern of a decrease in glutamine and glutamate with
an increase in aspartate is seen in both steroid-resistant
variants (until the CAT38 cells lose mitochondrial function)
in the presence and absence of dexamethasone. Dexameth-
asone is a cytostatic agent in lymphocytes in addition to
being cytotoxic [63,64]. The primary response to dexameth-
asone in Hb12 cells is cytostasis [36] where little de novo
synthesis of purines and pyrimidines is expected; however,
the amino acid pattern remains suggesting that de novo
purine and pyrimidine synthesis is not responsible for this
pattern. Cells use metabolites for multiple biochemical
processes simultaneously, therefore a combination of reac-
tions is probably occurring in these cells. The amino acid
pattern that is seen, combined with increased use of mito-
chondria for ATP production, suggests that glutaminolysis is
at least one of these processes.
4.2. Protective potential of metabolic alterations
Increased mitochondrial ATP production and glutaminol-
ysis may protect against the loss of glucose seen with
dexamethasone treatment. This is supported by data that a
yeast protein responsible for the diauxic shift, when over-
expressed in mammalian cells, protects from glucose dep-
rivation-induced apoptosis [65]. In yeast the diauxic shift is
a shift in metabolism from glycolysis to oxidative phos-
phorylation during nutrient limitation [65]. Overexpression
of Bcl-2 and catalase has resulted in WEHI7.2 variants that
are more resistant to ROS (manuscript in preparation). An
increased tolerance to ROS may allow cells to produce more
ATP via mitochondrial processes because mitochondria are
a major source of intracellular ROS [66]. Glucose depriva-
tion causes an increase in ROS production as the cells rely
on mitochondrial ATP production from glutamine and fatty
acids [24,67,68]. Glutaminolysis should be able to provide
ATP and reducing equivalents in the form of NADPH via
the reactions catalyzed by glutamate dehydrogenase, isoci-
trate dehydrogenase or malic enzyme (NADP malate dehy-
drogenase) [17,61] as long as glutamine is available. In
lymphocytes glutamine uptake does not appear to be affect-
ed by dexamethasone [69]. Cells overexpressing Bcl-2 or
catalase may be better able to accommodate increased
mitochondrial use because they are better able to tolerate
an increase in ROS which may prove lethal to WEHI7.2
cells. Alternatively, CAT38 and Hb12 cells may be better
able to survive an increase in demand for ATP production
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and glutaminolysis are already increased and thus the cells
are primed to respond.
4.3. Role for hexokinase in steroid-induced apoptosis
One critical difference between the WEHI7.2 and CAT38
cells which undergo apoptosis and the protected Hb12 cells
may be the loss of hexokinase activity over time in dexa-
methasone. WEHI7.2 cells are sensitive to steroids and
protection from steroid-induced apoptosis in CAT38 cells
is only temporary. This suggests that in these cells the same
event(s) occur, but with different kinetics. The drop in
hexokinase activity as the cells are undergoing apoptosis
is consistent with hexokinase playing a role in glucocorti-
coid-induced apoptosis similar to that during growth factor
withdrawal [32].
Increased hexokinase has been associated with protection
from apoptosis [32,56,57] while loss of mitochondrial hexo-
kinase activity has been associated with apoptosis [32]. In
healthy cells, hexokinase binds to the voltage-dependent
anion channel on the outer surface of the mitochondrial
membrane [70]. Loss of mitochondrial hexokinase from this
site can provide a place for Bax, a pro-apoptotic Bcl-2 family
member, to bind to the mitochondria and cause the release of
cytochrome c [71]. There is some evidence that Bax is
involved in glucocorticoid-induced thymocyte apoptosis.
Although thymocytes from Bax knockout mice show no
difference in dexamethasone sensitivity, thymocytes from
Bax/Bak double knockout mice are protected [72]. Bax and
Bak are both pro-apoptotic Bcl-2 family members with
somewhat redundant and overlapping functions and thus
activation of either may be sufficient to drive apoptosis
[72]. Mitochondrial hexokinase decreases over time in
dexamethasone in the apoptosis-sensitive WEHI7.2 cells
(between 12 and 24 h) and CAT38 cells (between 24 and
40 h) with timing that suggests it could play a role in
apoptosis. The critical event may be the actual decrease over
time indicating open sites for Bax binding rather than the
absolute concentration of hexokinase because the relative
number of hexokinase binding sites is unknown.
Hb12 cells maintain mitochondrial hexokinase in the
presence of dexamethasone, albeit at a lower specific activity
than in EtOH-treated cells. These cells do not undergo
apoptosis, indicating that the protection by Bcl-2 differs from
that of catalase overexpression. Bcl-2 is known to protect
cells from Bax at the mitochondrial level in other model
systems [73]. Bcl-2 and Bcl-XL also seem to protect cells by
maintaining mitochondrial integrity during adverse condi-
tions so that the cells can respond when favorable conditions
occur [22,23,74]. Maintenance of hexokinase on the mito-
chondrial membrane may contribute to this function of Bcl-2.
Data from other studies suggest at least two potential
effects of glucocorticoids on hexokinase. First, microarray
data have shown that dexamethasone down-regulates hexo-
kinase [42]. Our data support this effect at the protein level;total and mitochondrial hexokinase activity are decreased in
all the cells cultured in the presence of dexamethasone
compared to the EtOH-treated cells. Second, glucocorticoids
may affect mitochondrial hexokinase indirectly, via a de-
crease in glucose. Glucose or a glucose analog that can be
metabolized by hexokinase seems to be necessary to keep
the hexokinase bound to the mitochondria [32]. In FL5.12
cells, this seems to depend on activated Akt [32], but
preliminary data do not support a role for Akt in our model
(data not shown). Recently, it has been shown that Bad, one
of the proapoptotic Bcl-2 family members which is up-
stream of Bax/Bak, forms a complex with glucokinase on
the mitochondrial membrane in hepatocytes [75]. Since Bad
is activated during glucose deprivation, the authors suggest
that glucokinase acts as a sensor for glucose deprivation in
the activation of Bad [75]. Mitochondrial hexokinase may
perform a glucose sensing function in cells, such as lym-
phocytes, which do not contain glucokinase.
4.4. Metabolic alterations and tumorigenicity
The metabolic alterations seen in CAT38 and Hb12 cells
are also characteristic of cells that are more tumorigenic
[40,61,76–78]. Although WEHI7.2, CAT38 and Hb12 cells
are all tumorigenic in severe-combined immunodeficient
mice, CAT38 and Hb12 cells show increased tumor growth
compared to WEHI7.2 cells [14,15]. The metabolic flexibil-
ity and ability to maintain mitochondrial function may allow
the cells to survive, at least temporarily, in adverse condi-
tions. In Hanahan and Weinberg’s [79] model of the hall-
marks of cancer, two of the characteristics of cancer cells are
the insensitivity to anti-growth signals and evasion of
apoptosis. Overexpression of Bcl-2 and catalase, to a lesser
degree, has caused metabolic changes that help cells resist
apoptosis and may decrease sensitivity to anti-growth signals
(e.g. nutrient limitation) resulting in more tumorigenic cells.5. Conclusions
Taken together, these data suggest that the glucose
deprivation effect of glucocorticoids may contribute to
steroid-induced apoptosis by an increase in ROS production
[80] and/or a loss of hexokinase from the mitochondrial
membrane. The data also suggest that catalase and Bcl-2
overexpression affect basal metabolism resulting in cells
with altered metabolic profiles which are more characteristic
of tumor cell metabolic profiles than the parental cells.
These changes correlate with resistance to apoptosis and
increased tumorigenicity of these variants.Acknowledgements
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